KR102943479B1 - B형 간염 치료를 위한 면역원성 조성물 - Google Patents

B형 간염 치료를 위한 면역원성 조성물

Info

Publication number
KR102943479B1
KR102943479B1 KR1020217018153A KR20217018153A KR102943479B1 KR 102943479 B1 KR102943479 B1 KR 102943479B1 KR 1020217018153 A KR1020217018153 A KR 1020217018153A KR 20217018153 A KR20217018153 A KR 20217018153A KR 102943479 B1 KR102943479 B1 KR 102943479B1
Authority
KR
South Korea
Prior art keywords
hbsag
hepatitis
immunogenic composition
antigen
aluminum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018153A
Other languages
English (en)
Korean (ko)
Other versions
KR20210151047A (ko
Inventor
데이비드 에반다 앤더슨
탄비르 아메드
Original Assignee
브리 바이오사이언시스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리 바이오사이언시스 리미티드 filed Critical 브리 바이오사이언시스 리미티드
Publication of KR20210151047A publication Critical patent/KR20210151047A/ko
Application granted granted Critical
Publication of KR102943479B1 publication Critical patent/KR102943479B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020217018153A 2018-11-13 2019-11-13 B형 간염 치료를 위한 면역원성 조성물 Active KR102943479B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760439P 2018-11-13 2018-11-13
US62/760,439 2018-11-13
PCT/IB2019/001230 WO2020099927A1 (en) 2018-11-13 2019-11-13 Immunogenic compositions for treatment of hepatitis b

Publications (2)

Publication Number Publication Date
KR20210151047A KR20210151047A (ko) 2021-12-13
KR102943479B1 true KR102943479B1 (ko) 2026-03-27

Family

ID=70731781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018153A Active KR102943479B1 (ko) 2018-11-13 2019-11-13 B형 간염 치료를 위한 면역원성 조성물

Country Status (10)

Country Link
US (2) US12128100B2 (https=)
EP (1) EP3880244A4 (https=)
JP (2) JP2022513001A (https=)
KR (1) KR102943479B1 (https=)
CN (2) CN118987191A (https=)
BR (1) BR112021009234A2 (https=)
IL (2) IL314712A (https=)
MX (1) MX2021005588A (https=)
WO (1) WO2020099927A1 (https=)
ZA (1) ZA202103976B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099927A1 (en) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) * 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
AU2024313135A1 (en) 2023-06-23 2026-01-22 Brii Biosciences, Inc. Assessment and treatment of chronic hepatitis b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242812A (en) 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
CN1305527C (zh) 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN102949717A (zh) 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2018166298A1 (en) 2017-03-13 2018-09-20 Fudan University Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
WO2020099927A1 (en) * 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMAJ, 2001년, Vol.3, pp. 328-3322

Also Published As

Publication number Publication date
US20250269013A1 (en) 2025-08-28
EP3880244A1 (en) 2021-09-22
ZA202103976B (en) 2023-09-27
CA3119581A1 (en) 2020-05-22
KR20210151047A (ko) 2021-12-13
BR112021009234A2 (pt) 2021-09-08
US12128100B2 (en) 2024-10-29
IL283039B1 (en) 2024-09-01
JP2024174990A (ja) 2024-12-17
CN113423423A (zh) 2021-09-21
MX2021005588A (es) 2021-08-11
IL283039A (en) 2021-06-30
WO2020099927A1 (en) 2020-05-22
EP3880244A4 (en) 2022-08-17
US20230079703A1 (en) 2023-03-16
IL283039B2 (en) 2025-01-01
IL314712A (en) 2024-10-01
JP2022513001A (ja) 2022-02-07
CN113423423B (zh) 2024-08-13
CN118987191A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
Mohsen et al. Virus-like particle vaccinology, from bench to bedside
CN104043120B (zh) 乙型肝炎疫苗
KR102028463B1 (ko) 바리셀라 조스터 바이러스 백신
US20250269013A1 (en) Immunogenic compositions for treatment of hepatitis b
JPH085804B2 (ja) Ａ型及びｂ型肝炎混合アジュバントワクチン
JPH07505372A (ja) ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン
MX2009002561A (es) Vacuna.
US9683029B2 (en) Antibody composition for prevention or treatment of mutant hepatitis B virus infection
JP2023506439A (ja) 医薬組成物及びその用途
UA128952C2 (uk) Фармацевтична композиція, яка включає поверхневі і нуклеокапсидні антигени вірусу гепатиту в
CN110944662A (zh) 用于治疗和/或预防hbv感染的组合物及其用途
CN104873969B (zh) 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗
CZ20012544A3 (cs) Farmaceutické balení
US20240123060A1 (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
KR20190122717A (ko) 면역 증강제, 면역치료 약학적 조성물 및 이의 제조 및 용도
CA3119581C (en) Immunogenic compositions for treatment of hepatitis b
CN107693788B (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
HK40050381A (en) Immunogenic compositions for treatment of hepatitis b
HK40050381B (zh) 用於治疗乙型肝炎的免疫原性组合物
CN113058033B (zh) 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CN103566369A (zh) 一种在慢性乙肝病毒感染状态下诱导机体产生特异性免疫的乙肝疫苗
HK40062132A (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b.
HK40015475A (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
EA040981B1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
HK1259329B (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)